surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 surmount-1 trial tirzepatide weight loss

*Note: This newsletter may include affiliate links

Medicine 103 (29), e39026

A meta-regression analysis of GLP-1RA CVOT showed that the magnitude of HbA1c lowering, but not body weight (BW) loss, was associated with the prevention of renal outcomes [24]

Although there is no definitive research conclusion, attention should also be paid to the potential adverse consequences of carnitine deficiency for infants, which could even lead to pathological changes

Rea, Barbara Plitnick, Mariana G

Researchers started describing it as a genome reset, because the pattern in aged cells shifted back toward what youd expect from younger tissue (PMID: 25815981)